Meeting
2019 ASCO Annual Meeting
Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
Authors
Darren R. Feldman
Memorial Sloan Kettering Cancer Center, New York, NY
Darren R. Feldman , James S Hu , Sujata Patil , Victor E. Reuter , Sandy Srinivas , Walter Michael Stadler , Brian Addis Costello , Matthew I. Milowsky , Leonard Joseph Appleman , Tanya B. Dorff , Maria Bromberg , Gabriella Joseph , Samuel Aaron Funt , Dean F. Bajorin , George J. Bosl , David I. Quinn , Robert J. Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Germ Cell/Testicular
Clinical Trial Registration Number
NCT01873326
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4563)
DOI
10.1200/JCO.2019.37.15_suppl.4563
Abstract #
4563
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
First Author: Darren Richard Feldman
Poster
2021 ASCO Annual Meeting
Efficacy of TIP (paclitaxel, ifosfamide and cisplatin) as salvage chemotherapy for relapsed germ cell cancer patients stratified by the modified International Prognostic Factors Study Group (IPFSG) score: The Northern Ireland (NI) Experience.
First Author: Adam Uprichard
Poster
2015 Genitourinary Cancers Symposium
Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy.
First Author: Orvar Gunnarsson
Poster
2023 ASCO Annual Meeting
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).
First Author: Danka Sinikovic Zebic